Conference - Houston, TX, United States
Speakers at this meeting will present the newest and often unpublished data that relate to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) Aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells and approaches to cure.
THE PROGRAM WILL INCLUDE:
• John Goldman Prize
• Janet Rowley Prize
• ERSAP Prize
• Keynote lectures
• Special lectures
• Oral communications selected from submitted abstracts
• Brief oral communications selected from submitted abstracts
• Workshops for non-clinical scientists
• Clinical and biology manned poster walks
• Clinical symposium on Modern Diagnostics and
• Satellite symposia
For more information, please visit: http://www.esh.org/conference/18th-annual-john-goldman-conference-on-chronic-myeloid-leukemia-biology-and-therapy
Thursday, September 15, 2016 to Sunday, September 18, 2016
Uptown, 2222, West Loop South Freeway Houston United States of America
Houston, Texas, U.S.A.
Contact: nicolas.jaillard@univ-paris-diderot.fr
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
